Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Mologen AG (MGK GN) NPV

Sell:€0.0958 Buy:€0.11 Change: No change
Market closed |  Prices as at close on 20 February 2020 | Switch to live prices |
Sell:€0.0958
Buy:€0.11
Change: No change
Market closed |  Prices as at close on 20 February 2020 | Switch to live prices |
Sell:€0.0958
Buy:€0.11
Change: No change
Market closed |  Prices as at close on 20 February 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.

Contact details

Address:
Fabeckstr. 30
BERLIN
14195
Germany
Telephone:
+49 (3084) 17880
Website:
www.mologen.com/de/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MGK GN
ISIN:
DE000A2LQ900
Market cap:
€1.27 million
Shares in issue:
12.44 million
Sector:
Biotechnology
Exchange:
Xetra
Country:
Germany
Currency:
Euro
Indices:
n/a

Key personnel

  • Oliver Krautscheid
    Chairman of the Supervisory Board
  • Stefan Manth
    Chief Executive Officer, Member of the Executive Board
  • Walter Miller
    Chief Financial Officer, Member of the Executive Board
  • Matthias Baumann
    Chief Medical Officer, Member of the Executive Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.